

# 8<sup>th</sup> Australian Lung Cancer Conference

Melbourne Convention and Exhibition Centre  
19 - 21 February 2020

A time of *hope*  
in lung cancer

Thanks to our event sponsors:

Platinum



AstraZeneca



Gold



Bristol-Myers Squibb



MSD

Silver



Lung Foundation Australia  
Celebrating 30 Years

In collaboration with:



Lung Foundation Australia  
ANZ Lung Cancer Nurses Forum



ALTC  
Australasian Lung Cancer Trials Group



# Methods

Starting point: Retrospective analyses of all incident Qld NSCLC patients 2011-2016



N = 10,961

A time of *hope* in lung cancer

Selected patients treated with IV systemic therapy



N = 4,690  
(42% of NSCLC patients)

Any death recorded within 30 days of last IV systemic therapy treatment



N = 1,076  
(23% of patients treated with IV systemic therapy)



In collaboration with:



# Patient characteristics

- More males diagnosed
- Similar treatment rates across socio-economic status
- Slightly lower treatment rates among outer regional & remote patients
- 46% diagnosed at stage IV
- Systemic therapy rates highest in stage III and II

	NSCLC		Had IVST	
	Count	% of all patients with NSCLC	Count	% of NSCLC
<b>Queensland</b>	<b>10961</b>		<b>4690</b>	<b>43%</b>
<b>Sex</b>				
Male	6591	60%	2832	43%
Female	4370	40%	1858	43%
<b>Age group</b>				
<50	381	3%	250	66%
50-59	1518	14%	912	60%
60-69	3397	31%	1835	54%
70-79	3607	33%	1449	40%
80+	2058	19%	244	12%
<b>Socioeconomic status</b>				
Affluent	1136	10%	509	45%
Middle	7003	64%	3060	44%
Disadvantaged	2822	26%	1121	40%
<b>Facility type</b>				
Public			3025	..
Private			1665	..
<b>Comorbidity group</b>				
0	5054	46%	2536	50%
1	3309	30%	1306	39%
2+	2598	24%	848	33%
<b>Residence at diagnosis</b>				
Major city	6798	62%	2985	44%
Inner regional	2640	24%	1150	44%
Outer regional and remote	1523	14%	555	36%
<b>Indigenous status</b>				
Indigenous	338	3%	136	40%
Non-Indigenous	10619	97%	4554	43%
Not Stated/Unknown	4	0%	0	0%
<b>Stage group at diagnosis</b>				
I	1845	17%	455	25%
II	822	7%	478	58%
III	1499	14%	996	66%
IV	5093	46%	2262	44%
Not Known	1702	16%	499	29%

**8<sup>th</sup> Australian Lung Cancer Conference**  
Melbourne Convention and Exhibition Centre  
19 - 21 February 2020

- 43% of patients received IV systemic therapy



In collaboration with:



This is a brief extract from the presentation.  
If you would like more information, please contact us



[CancerAllianceQld@health.qld.gov.au](mailto:CancerAllianceQld@health.qld.gov.au)



*cancer alliance*  
queensland